The Science of Selling: Selling Science to Non-Scientists
Business & Innovation: Chemical Entrepreneurship Series
“The Science of Selling: Selling Science to Non-Scientists” A short presentation followed by Q&A with speakers Carol Nacy, CEO at Sequella, and Juliane Snowden, VP at Burns McClellan.
You have a great scientific idea – but you are puzzled about how to sell it. To be successful, today’s scientists need to be more than just great scientists. One needs to know how to pare down complex technical issues and make it relevant to the business audience. Join our speakers Carol Nacy, CEO at Sequella, and Juliane Snowden, VP at Burns McClellan, as they provide you with valuable internal and external business perspectives and tips to successfully get others to ‘buy your science’.
Congratulations to Imen Hannachi who attended LIVE and won!
Imen will receive an hour of coaching on ‘selling your science’ with our subject expert Juliane Snowden from Burns McClellan
What You Will Learn
- Thinking about science in terms accessible to everyone
- Relating science to business objectives
- The importance of consistent messaging
- And much more…
Webinar Details
Date: Thursday, August 18, 2011
Time: 2:00-3:00 pm ET
Fee: Free
Meet Your Experts
Dr. Nacy is founder, CEO and Chair of the Board of Sequella, Inc., a privately-held pharmaceutical company in Rockville, MD. Prior to Sequella, Dr. Nacy was Chief Scientific Officer (1997-1998) for Anergen, Inc., acquired by Corixa Corporation in 1998, and Executive VP and Chief Scientific Officer at EntreMed, Inc., from 1993 through its successful public offering in June 1996. She is a member of the Boards of Directors of for-profit companies and non-profit agencies. Prior to her business experience, Dr. Nacy was career scientist and science manager for 17 years at the Walter Reed Army Institute of Research in Washington, DC. She has published over 150 scientific papers.
Juliane Snowden joined Burns McClellan as Vice President in May 2006, having honed her communications skills for the past 13 years with a solid investor relations track record and broad experience in corporate communications, including branding and messaging, media relations, crisis communications, and relationship development and management. Ms. Snowden’s most recent corporate position was as Director, Corporate Communications for Ventana Medical Systems, and her corporate experience includes Merck & Co., Inc., Reliant Pharmaceuticals, and Applied Biosciences Inc. Ms. Snowden also has a wealth of experience as a consultant, having led the life sciences investor relations practices at Thomson Financial, Cohn & Wolf, and for her own business, Snowden & Associates.
Meet the Moderator
Dr. Spellmeyer joined Nodality in September of 2006. Prior to Nodality, he held positions as a research staff member in the IBM Almaden Services Research group, as chief scientific officer and vice president of drug discovery at Signature BioSciences, as executive director at DuPont Pharmaceuticals, as vice president at CombiChem, and a principal scientist at Chiron. Dr. Spellmeyer received his Ph.D. in 1987 from UCLA, and completed his post-doctoral work in pharmaceutical chemistry at UCSF. He continues his interaction with the UCSF research groups through his adjunct assistant professorship. He has authored more than 35 scientific publications and two modeling packages, and frequently makes presentations at scientific seminars.
The Fine Print
ACS Webinars™ does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.